Lenvatinib Phase III results show significant improvement in progression-free survival in people with Radioiodine-Refractory differentiated Thyroid Cancer
Pivotal phase III data for lenvatinib to be presented in a Head and Neck Cancer oral session at American Society of Clinical Oncology congress (ASCO) – Press Release.